Virtual presentation to be available starting
on September 11, 2023, at
7 AM Eastern Time
TEL
AVIV, Israel, Aug. 29,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company
developing innovative therapeutics to treat rare fibro-inflammatory
diseases with high unmet need, today announced that Adi Mor,
PhD, co-founder, Chief Executive Officer and Chief Scientific
Officer of Chemomab, will present virtually at the H.C. Wainwright
25th Annual Global Investment Conference being held
September 11-15, 2023.
Investors may view the Chemomab presentation online beginning
on September 11, 2023, at 7:00 AM ET via the
following link:
https://journey.ct.events/view/cfe7b944-a4a2-444a-97d8-702be00cac82.
This link will remain active for 90 days. It will also be
available at the investor section of the Chemomab website at
https://investors.chemomab.com/events.
Chemomab senior management will be available for virtual
one-on-one meetings with investors during the conference from
September 11 through September 14,
2023. For information about the conference and to register
to meet with Chemomab management, visit
https://hcwevents.com/annualconference/.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to neutralize CCL24 activity. In preclinical and clinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported encouraging results from three clinical trials of
CM-101 in patients, including a Phase 2 liver fibrosis trial and an
investigator-initiated study in patients with severe lung injury. A
Phase 2 trial in primary sclerosing cholangitis patients is
ongoing, with topline data expected in the second half of 2024. For
more information about Chemomab, visit chemomab.com.
Contact:
Media and Investors:
Barbara
Lindheim
Consulting Vice President, Investor &
Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301912009.html
SOURCE Chemomab Therapeutics, Ltd.